The article provides an overview of the opinions of 14 analysts on PTC Therapeutics stock. The average 12-month price target has increased by 1.68% from the previous average, indicating a slightly positive sentiment. However, the ratings are mixed, with 4 bullish, 2 somewhat bullish, 6 indifferent, 1 somewhat bearish, and 1 bearish. This suggests that the short-term impact on the stock price is likely to be neutral, as the overall sentiment is not strongly positive or negative.